Pharming Group (NASDAQ:PHAR) Upgraded to Hold at Wall Street Zen

Pharming Group (NASDAQ:PHAR) was upgraded by Wall Street Zen to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

Several other research analysts also recently commented on the company. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Canaccord Genuity Group set a $38.00 target price on Pharming Group in a report on Wednesday, September 23rd. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research note on Tuesday, September 22nd. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Pharming Group currently has an average rating of “Hold” and a consensus price target of $38.67.

Pharming Group Stock Performance

NASDAQ:PHAR opened at $11.20 on Friday. The firm has a market cap of $792.74 million, a price-to-earnings ratio of 93.33 and a beta of -0.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. Pharming Group has a 52-week low of $9.11 and a 52-week high of $21.34. The business’s fifty day moving average is $10.67 and its 200 day moving average is $12.62.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. Research analysts predict that Pharming Group will post 0.22 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP bought a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises about 6.0% of MAC Alpha Capital Management LP’s holdings, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.